Copy Number Variation (CNV) Reference Products

How Do You Know About Cancer CNVs?

Gene copy numbers, referred to as copy number variants (CNVs), constitute a pivotal aspect of our genetic composition, exerting significant influence on diverse traits and our susceptibility to diseases. These CNVs, particularly within specific genes, have been intricately associated with a wide range of cancers, influencing the initiation, progression, and development of these malignancies by modulating gene expression levels.

The detection of CNVs hinges on the utilization of advanced sequencing technologies, such as whole-exome sequencing or whole-genome sequencing. These cutting-edge methodologies empower precise determination of the copy numbers of individual genes and the identification of any atypical variations in copy numbers.

However, it is imperative to underscore that the reliability and accuracy of CNV testing crucially depend on the utilization of a high-quality reference genome. Typically, this reference genome involves DNA samples extracted from healthy individuals, serving as benchmarks for CNV assessment. To uphold the credibility and validity of CNV analysis, the reference genome must meet stringent criteria, encompassing high-quality data, precision, and representativeness. This meticulous approach ensures the robustness of CNV detection and its clinical implications.

Product Details

Realistic Clinical Simulation: A diverse range of CNV profiles associated with prevalent cancers, including lung, brain, and breast cancer. We provide different formats, including gDNA, FFPE. This empowers laboratories to faithfully emulate CNV profiles observed in real patients during both research and clinical assessments. As a result, it enhances the clinical significance of experimental outcomes.

Cost-Efficiency Redefined: A singular sample encompassing three clinically relevant CNVs. This strategic design significantly reduces the overall costs related to specimen collection and sequencing. Laboratories can harness this single sample to develop, optimize, and validate CNV assays without the necessity of procuring multiple independent samples.

Comprehensive Multi-Gene Coverage: A spectrum of pivotal genes associated with various cancer types, including EGFR, MYCN, MET, ERBB2, FGFR3, and MYC. This comprehensive gene inclusion broadens the horizons of CNV analysis, enabling researchers to explore CNV profiles across multiple genes simultaneously.

Unwavering Experimental Reproducibility: By employing the CD CNV Reference Mixture, laboratories gain access to stable and consistent samples that can be used for the validation and comparative assessment of diverse CNV assays. This ensures a high degree of consistency and confidence in experimental findings.

Advancing (pre-)Clinical Research: An invaluable asset for cancer research and clinical investigations. It facilitates a deeper understanding of the intricate relationship between CNV patterns and cancer progression, as well as treatment response. Consequently, it provides critical insights for more informed decision-making in cancer treatment strategies.

Applications

Advanced CNV Assay Development: Laboratories can harness the CD CNV Reference Mixture for the advanced development, fine-tuning, and rigorous validation of CNV assays. These meticulously crafted methods find pivotal utility in both cutting-edge research and clinical diagnostics, aiding in the precise determination of a patient's CNV profile.

Empowering Drug Development: The CD CNV Reference Mixture emerges as a powerful tool in the realm of drug development, particularly for pharmaceuticals targeting CNV-driven cancer therapies. Researchers can leverage this versatile mixture to meticulously evaluate drug efficacy and meticulously select the most promising treatment strategies.

Precision Clinical Diagnostics: In the arena of clinical diagnostics, CD CNV Reference Mixtures prove instrumental in assisting physicians in ascertaining a patient's CNV status. This invaluable information enables healthcare professionals to craft tailored treatment plans and anticipate treatment responses with a heightened level of accuracy.

Pioneering Disease Research: CD CNV Reference Mixtures propel disease research, particularly in the context of CNVs associated with prevalent cancers like lung, brain, and breast cancers. These mixtures serve as a beacon illuminating the intricate role of CNVs in the progression of diseases, thereby contributing to the ongoing quest for innovative solutions and treatments.

* For research purposes only, not intended for clinical diagnosis, treatment, or individual health assessments.

Explore Our Copy Number Variation (CNV) Reference Products:

Filter by

Cat. No.	Product Name	Brief Description
CNVR001	CD Cancer CNV Reference Mix (EGFR/MYCN/MET), 6 copies	CD CNV Reference Mix offers an extensive selection of essential genes associated with lung, brain, and breast cancers, including EGFR, MYCN, MET, ERBB2, FGFR3, and MYC, each represented with varying copies reflecting the diverse CNV landscape in these cancers.
CNVR002	CD Cancer CNV Reference Mix (EGFR/MYCN/MET), 3 copies	CD CNV Reference Mix offers an extensive selection of essential genes associated with lung, brain, and breast cancers, including EGFR, MYCN, MET, ERBB2, FGFR3, and MYC, each represented with varying copies reflecting the diverse CNV landscape in these cancers.
CNVR003	CD Cancer CNV Reference Mix (EGFR/MYCN/MET), 12 copies	CD CNV Reference Mix offers an extensive selection of essential genes associated with lung, brain, and breast cancers, including EGFR, MYCN, MET, ERBB2, FGFR3, and MYC, each represented with varying copies reflecting the diverse CNV landscape in these cancers.
CNVR004	CD FFPE Solid Tumor CNV Reference, 12 genes	CD FFPE CNV Reference Mix offers an extensive selection of essential genes associated with solid tumors, including 12 genes, AKT2, BRAF, EGFR, ERBB2, FGFR3, KIT, KRAS, MET, MYC, MYCN, NTRK1, PIK3CA, each represented with varying copies reflecting the diverse CNV landscape in these cancers.
CNVR005	CD Cancer CNV Reference Mix (ERBB2/FGFR3/MYC), 6 copies	CD CNV Reference Mix offers an extensive selection of essential genes associated with lung, brain, and breast cancers, including EGFR, MYCN, MET, ERBB2, FGFR3, and MYC, each represented with varying copies reflecting the diverse CNV landscape in these cancers.
CNVR006	CD Cancer CNV Reference Mix (ERBB2/FGFR3/MYC), 3 copies	CD CNV Reference Mix offers an extensive selection of essential genes associated with lung, brain, and breast cancers, including EGFR, MYCN, MET, ERBB2, FGFR3, and MYC, each represented with varying copies reflecting the diverse CNV landscape in these cancers.
CNVR007	CD Cancer CNV Reference Mix (ERBB2/FGFR3/MYC), 12 copies	CD CNV Reference Mix offers an extensive selection of essential genes associated with lung, brain, and breast cancers, including EGFR, MYCN, MET, ERBB2, FGFR3, and MYC, each represented with varying copies reflecting the diverse CNV landscape in these cancers.
CNVR008	CD Solid Tumor CNV Reference Mix, 6 copies, 12 genes	CD CNV Reference Mix offers an extensive selection of essential genes associated with solid tumors, including 12 genes, AKT2, BRAF, EGFR, ERBB2, FGFR3, KIT, KRAS, MET, MYC, MYCN, NTRK1, PIK3CA, each represented with varying copies reflecting the diverse CNV landscape in these cancers.
CNVR009	CD Solid Tumor CNV Reference Mix, 3 copies, 12 genes	CD CNV Reference Mix offers an extensive selection of essential genes associated with solid tumors, including 12 genes, AKT2, BRAF, EGFR, ERBB2, FGFR3, KIT, KRAS, MET, MYC, MYCN, NTRK1, PIK3CA, each represented with varying copies reflecting the diverse CNV landscape in these cancers.
CNVR010	CD Solid Tumor CNV Reference Mix, 12 copies, 12 genes	CD CNV Reference Mix offers an extensive selection of essential genes associated with solid tumors, including 12 genes, AKT2, BRAF, EGFR, ERBB2, FGFR3, KIT, KRAS, MET, MYC, MYCN, NTRK1, PIK3CA, each represented with varying copies reflecting the diverse CNV landscape in these cancers.

We use cookies to understand how you use our site and to improve the overall user experience. This includes personalizing content and advertising. Read our Privacy Policy

Accept Cookies